北京赛升药业股份有限公司 2020 年年度报告全文 北京赛升药业股份有限公司 2020 年年度报告 2021-026 2021 年 03 月 1 北京赛升药业股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节第九项"公司未来发展的展望"部分对公司未来发 展 战略、2021 年经营计划及可能面对的风险因素进行了详细阐述，请投资者注 意 阅读。 公司经本次董事会审议通过的利润分配预案为：以 481666400 为基数，向 全体股东每 10 股派发现金红利 0.65 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 0 股。 2 $$\mathbb{H}{\overline{{\mathbb{X}}}}^{*}$$ | 第一节 ...

北京赛升药业股份有限公司 2020 年第三季度报告全文 北京赛升药业股份有限公司 2020 年第三季度报告 2020-069 2020 年 10 月 1 北京赛升药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,950,466,156.88 | 2,805,502,672.29 | | 5.17% | | 归属于上市公司股 ...

北京赛升药业股份有限公司 2020 年半年度报告全文 北京赛升药业股份有限公司 2020 年半年度报告 2020-050 2020 年 08 月 1 北京赛升药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节"经营情况讨论与分析"第九项"公司面临的风险 和应对措施"部分对公司可能面对的风险因素进行了详细阐述，请投资者注意 阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 北京赛升药业股份有限公司 2020 年半年度报告全文 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 本公司、公司、赛升药业 | 指 | 北京赛升药业股份有限公司 | | 控股股东、实际控制人 | 指 | 马骉 | | ...

[Important Notice](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section confirms the company's management and accounting personnel's assurance of the quarterly report's accuracy and completeness, along with their legal responsibilities [Board of Directors' Statement](index=2&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%A3%B0%E6%98%8E) The company's Board of Directors, Supervisory Board, and senior management collectively affirm the truthfulness, accuracy, and completeness of this quarterly report and assume legal responsibility - The company's management (Board of Directors, Supervisory Board, and senior executives) jointly guarantee the **truthfulness, accuracy, and completeness** of this quarterly report and assume corresponding legal responsibilities[4](index=4&type=chunk) - The company's principal officer, the person in charge of accounting, and the head of the accounting department all declare to guarantee the **truthfulness, accuracy, and completeness** of the financial statements[5](index=5&type=chunk) [Company Profile](index=3&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section details the company's Q1 2020 financial performance, including revenue and profit declines, strong operating cash flow, and key shareholder information [Key Accounting Data and Financial Indicators](index=3&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company experienced a Q1 2020 revenue decline of 14.32% and net profit drop of 43.19%, yet operating cash flow significantly increased by 299.18% Key Financial Indicators for Q1 2020 | Item | Current Period | Prior Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue (Yuan) | 167,249,354.70 | 195,202,444.15 | -14.32% | | Net Profit Attributable to Shareholders (Yuan) | 25,443,560.16 | 44,784,087.10 | -43.19% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (Yuan) | 21,433,615.30 | 40,500,251.33 | -47.08% | | Net Cash Flow from Operating Activities (Yuan) | 35,097,216.95 | 8,792,310.69 | 299.18% | | Basic Earnings Per Share (Yuan/share) | 0.050 | 0.090 | -44.44% | | Weighted Average Return on Net Assets | 0.95% | 1.74% | -0.79% | Non-recurring Gains and Losses for Q1 2020 | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses from Entrusted Investments or Asset Management | 1,799,613.50 | | Fair Value Change Gains/Losses from Financial Assets Held for Trading | 3,192,905.66 | | Other Non-operating Income and Expenses | -274,936.97 | | Income Tax Impact | -707,637.33 | | **Total** | **4,009,944.86** | [Shareholder Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) The company had 24,882 common shareholders, with controlling shareholder Ma Biao and related family members holding a significant combined stake - At the end of the reporting period, the company had a total of **24,882** common shareholders[12](index=12&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Shareholder Type | Holding Percentage | Number of Shares Held | | :--- | :--- | :--- | :--- | | Ma Biao | Domestic Natural Person | 49.25% | 238,464,000 | | Ma Li | Domestic Natural Person | 11.18% | 54,125,791 | | Liu Shuqin | Domestic Natural Person | 2.41% | 11,664,000 | - The top three shareholders, Ma Biao, Ma Li, and Liu Shuqin, have related party relationships: Ma Biao and Ma Li are siblings, and Liu Shuqin is their mother[14](index=14&type=chunk) [Significant Events](index=6&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details significant financial changes, including asset and profit shifts, the impact of COVID-19 on business, and the status of raised funds utilization [Significant Changes in Key Financial Data and Their Reasons](index=6&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) Significant financial changes include a 928.68% increase in fixed assets, a 258.06% surge in R&D expenses, a 45.44% drop in operating profit, and a 299.18% rise in operating cash flow - Balance Sheet Item Changes: - **Fixed Assets**: Increased by **928.68%** year-over-year, primarily due to the capitalization of construction in progress projects - **Construction in Progress**: Decreased by **93.51%** year-over-year, due to conversion to fixed assets - **Financial Assets Held for Trading**: Increased by **51.33%** year-over-year, mainly due to increased short-term bank wealth management investments[18](index=18&type=chunk) - Income Statement Item Changes: - **Research and Development Expenses**: Increased by **258.06%** year-over-year, due to the company's increased R&D investment - **Operating Profit**: Decreased by **45.44%** year-over-year, primarily impacted by reduced sales revenue and increased R&D investment - **Net Profit Attributable to Parent Company Shareholders**: Decreased by **43.19%** year-over-year, mainly due to reduced sales revenue[22](index=22&type=chunk) - Cash Flow Statement Item Changes: - **Net Cash Flow from Operating Activities**: Increased by **299.18%** year-over-year, primarily due to reduced tax and fee payments in the current period - **Net Cash Flow from Investing Activities**: Decreased by **218.28%** year-over-year, mainly due to increased purchases of short-term wealth management products in the current period[24](index=24&type=chunk) [Business Review and Outlook](index=8&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E5%8A%A1%E5%9B%9E%E9%A1%BE%E5%92%8C%E5%B1%95%E6%9C%9B) Q1 revenue declined 14.32% due to COVID-19 impacts, while the company actively supported epidemic control and disclosed key risks including policy, market, quality, R&D, and talent retention - In Q1 2020, the company achieved operating revenue of **167 million Yuan**, a year-over-year decrease of **14.32%**; net profit attributable to parent company shareholders was **25.44 million Yuan**, a year-over-year decrease of **43.19%**[24](index=24&type=chunk) - The company actively responded to the COVID-19 pandemic by urgently resuming work during the Spring Festival to produce and donate immune-modulating drugs, such as Thymosin Alpha 1 for Injection and Polysaccharide Peptide Injection, to support epidemic prevention and control[25](index=25&type=chunk) - The company completed a **$1.6 million** investment in overseas entity Curiato INC through its Hong Kong subsidiary[25](index=25&type=chunk) - The company faces major risks including: pharmaceutical industry policy risks (e.g., centralized procurement, medical insurance cost control), market development and product price reduction risks, product quality risks, new drug R&D failure risks, and core personnel loss risks[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) [Use of Raised Funds](index=11&type=section&id=%E4%BA%94%E3%80%81%E5%8B%9F%E9%9B%86%E8%B5%84%E9%87%91%E4%BD%BF%E7%94%A8%E6%83%85%E5%86%B5%E5%AF%B9%E7%85%A7%E8%A1%A8) The company has invested 652 million Yuan of its 1.081 billion Yuan raised funds, with key projects completed but regulatory filings delayed, leaving 548 million Yuan unused Overview of Raised Funds Utilization (Unit: Ten Thousand Yuan) | Item | Amount | | :--- | :--- | | Total Raised Funds | 108,094.47 | | Total Investment This Quarter | 894.82 | | Total Cumulative Investment | 65,200.07 | | Unused Raised Funds | 54,773.51 | - The "New Pharmaceutical Production Base Project" and "New Cardiovascular and Immune-Modulating Product Industrialization Project" were completed and capitalized in December 2019, but regulatory filing progress is behind schedule due to institutional reforms and the pandemic[35](index=35&type=chunk) - As of March 31, 2020, unused raised funds are held in dedicated bank accounts, time deposits, and wealth management products awaiting redemption[36](index=36&type=chunk) [Financial Statements](index=14&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section provides the company's unaudited Q1 2020 consolidated financial statements, including the balance sheet, income statement, and cash flow statement, along with an explanation of accounting policy changes [Consolidated Financial Statements](index=14&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's Q1 2020 consolidated balance sheet, income statement, and cash flow statement, detailing key financial performance metrics [Consolidated Balance Sheet](index=14&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of March 31, 2020, total assets reached 2.818 billion Yuan, total liabilities were 66.39 million Yuan, and parent company equity was 2.704 billion Yuan Key Consolidated Balance Sheet Items (March 31, 2020) | Item | Amount (Yuan) | | :--- | :--- | | **Total Assets** | **2,818,250,325.92** | | Total Current Assets | 1,611,151,832.92 | | Total Non-current Assets | 1,207,098,493.00 | | **Total Liabilities** | **66,393,021.62** | | **Total Equity Attributable to Parent Company Owners** | **2,704,263,114.95** | [Consolidated Income Statement](index=19&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Q1 2020 saw operating revenue of 167 million Yuan, a 14.32% decrease, and net profit attributable to parent company owners of 25.44 million Yuan, a 43.19% decline Key Consolidated Income Statement Items (Q1 2020) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Operating Revenue | 167,249,354.70 | 195,202,444.15 | | Total Operating Costs | 147,158,831.03 | 153,838,864.46 | | Research and Development Expenses | 11,957,633.10 | 3,339,538.91 | | Operating Profit | 28,624,611.60 | 52,466,497.81 | | Net Profit Attributable to Parent Company Owners | 25,443,560.16 | 44,784,087.10 | | Basic Earnings Per Share | 0.050 | 0.090 | [Consolidated Cash Flow Statement](index=24&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Q1 2020 saw operating cash flow increase by 299.18% to 35.10 million Yuan, while investing cash flow was -293 million Yuan, and financing cash flow was 15 million Yuan Key Consolidated Cash Flow Statement Items (Q1 2020) | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 35,097,216.95 | 8,792,310.69 | | Net Cash Flow from Investing Activities | -293,295,337.50 | 247,974,472.74 | | Net Cash Flow from Financing Activities | 15,000,000.00 | 0.00 | | Net Increase in Cash and Cash Equivalents | -243,198,120.55 | 256,766,783.43 | [Explanation of Financial Statement Adjustments](index=28&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E8%B0%83%E6%95%B4%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company adopted new revenue and lease accounting standards from January 1, 2020, with no adjustments to the opening financial statements - The company first adopted new revenue and lease accounting standards starting in **2020**, but this accounting policy change did not result in adjustments to relevant items in the opening financial statements for the current period[76](index=76&type=chunk)[77](index=77&type=chunk)[80](index=80&type=chunk) [Audit Report](index=31&type=section&id=%E4%B8%89%E3%80%81%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) The company's Q1 2020 financial report remains unaudited - The company's **Q1 2020** financial report is unaudited[84](index=84&type=chunk)

北京赛升药业股份有限公司 2019 年年度报告全文 北京赛升药业股份有限公司 2019 年年度报告 2020-010 2020 年 04 月 1 北京赛升药业股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司已在本报告第四节第九项"公司未来发展的展望"部分对公司未来发 展 战略、2020 年经营计划及可能面对的风险因素进行了详细阐述，请投资者 注意 阅读。 公司经本次董事会审议通过的利润分配预案为：以 484,166,000 为基数， 向全体股东每 10 股派发现金红利 0.62 元（含税），送红股 0 股（含税），以资 本公积金向全体股东每 10 股转增 0 股。 2 | 第一节重要提示、目录和释义 2 | | --- | | 第二节公司简介和主要财务指标 6 | | ...

北京赛升药业股份有限公司 2019 年第三季度报告全文 北京赛升药业股份有限公司 2019 年第三季度报告 2019-068 2019 年 10 月 1 北京赛升药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 √ 适用 □ 不适用 单位：人民币元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | 7,908.77 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 10,706.00 | | | 委托他人投资或管理资产的损益 | 14,869,979.57 | | | 除上述各项之外的其他营业外收入和支出 | ...

北京赛升药业股份有限公司 2019 年半年度报告全文 北京赛升药业股份有限公司 2019 年半年度报告 2019-045 2019 年 08 月 1 北京赛升药业股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、 医药行业政策风险 近年来，国家对医药行业的监管力度不断加强，医疗与医药体制改革持续 深化。受药品集中采购、医保政策、注册审核、"两票制"、带量采购、一致性 评价、药品谈判、价格管理、药占比管理、重点监控目录等政策或措施相继出 台的影响，对整个行业在行业准入、生产与质量管理、销售、研发与注册等方 面的要求均大幅提升，企业需要快速达到并适应新的要求，客观上使得企业政 策风险增加。 2、 市场开拓及产品价格下降风险 目前公司的营销网络体系覆盖全国主要城市 ...

北京赛升药业股份有限公司 2019 年第一季度报告全文 北京赛升药业股份有限公司 2019 年第一季度报告 2019-023 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 2019 年 04 月 1 北京赛升药业股份有限公司 2019 年第一季度报告全文 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 195,202,444.15 | 270,473,451.39 | -27.83% | | 归属于上市公司股东的净利润（元） | 44,784,087.10 ...

北京赛升药业股份有限公司 2019 年第一季度报告全文 北京赛升药业股份有限公司 2019 年第一季度报告 2019-021 2019 年 04 月 1 北京赛升药业股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 195,202,444.15 | 270,473,451.39 | -27.83% | | 归属于上市公司股东的净利润（元） | 44,784,087.10 ...

[Important Notice, Table of Contents and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) [Risk Factors](index=2&type=section&id=1.1%20%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company faces key risks from pharmaceutical policy shifts, market competition, product quality, R&D failures, and core talent loss, potentially impacting its performance - The company faces five core risks - **Pharmaceutical Industry Policy Risk**: Policies such as centralized drug procurement, medical insurance policies, 'two-invoice system', and volume-based procurement increase compliance and operational risks for the company[6](index=6&type=chunk) - **Market Expansion and Price Decline Risk**: Drug tendering, medical insurance payment reforms, and intensified market competition may lead to a decrease in the company's product prices, affecting profitability[7](index=7&type=chunk) - **Product Quality Risk**: The company's main products are injections with complex production processes, where issues at any stage could lead to quality risks[8](index=8&type=chunk) - **New Drug R&D Risk**: New drug development involves long cycles and multiple stages, with risks of development failure or market rejection, potentially impacting the company's growth[10](index=10&type=chunk) - **Core Personnel Turnover Risk**: As a high-tech enterprise, the loss of core technical and management personnel could adversely affect the company's R&D and stable development[11](index=11&type=chunk) [Profit Distribution Plan](index=3&type=section&id=1.2%20%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E9%A2%84%E6%A1%88) The company's board of directors approved the 2018 profit distribution plan, proposing a cash dividend of 1.20 Yuan (tax inclusive) per 10 shares to all shareholders, with no bonus shares or capital reserve conversions 2018 Annual Profit Distribution Plan | Distribution Method | Per 10 Shares Distribution Plan | | :--- | :--- | | Cash Dividend | 1.20 Yuan (tax inclusive) per 10 shares | | Bonus Shares | 0 shares | | Capital Reserve Conversion | 0 shares | [Company Profile and Key Financial Indicators](index=7&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) [Key Accounting Data and Financial Indicators](index=8&type=section&id=2.1%20%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In 2018, the company's operating revenue significantly grew by **90.37%** to **1.428 billion Yuan**, while net profit attributable to shareholders slightly increased by **0.53%** to **283 million Yuan**, with basic earnings per share remaining flat, and net cash flow from operating activities increasing by **35.40%** Key Financial Indicators for 2018 | Indicator | 2018 | 2017 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 1,427,750,943.80 | 749,986,848.13 | 90.37% | | Net Profit Attributable to Shareholders (Yuan) | 283,107,048.21 | 281,604,133.53 | 0.53% | | Net Cash Flow from Operating Activities (Yuan) | 146,516,272.45 | 108,212,673.95 | 35.40% | | Basic Earnings Per Share (Yuan/share) | 0.590 | 0.590 | 0.00% | | Weighted Average Return on Net Assets | 11.66% | 12.79% | -1.13% | | Total Assets (Yuan) | 2,760,559,359.20 | 2,453,403,315.15 | 12.52% | 2018 Quarterly Key Financial Indicators (Unit: Yuan) | Indicator | Q1 | Q2 | Q3 | Q4 | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 270,473,451.39 | 302,671,052.82 | 366,543,603.57 | 488,062,836.02 | | Net Profit Attributable to Shareholders | 59,865,789.84 | 71,938,904.25 | 78,361,425.99 | 72,940,928.13 | - The company's 2018 non-recurring gains and losses totaled **20.79 million Yuan**, primarily from gains and losses on entrusted investments or asset management, amounting to **23.23 million Yuan**[30](index=30&type=chunk) [Company Business Overview](index=10&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E5%85%AC%E5%8F%B8%E4%B8%9A%E5%8A%A1%E6%A6%82%E8%A6%81) [Main Business and Core Competencies](index=10&type=section&id=3.1%20%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1%E4%B8%8E%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B) The company's main business involves R&D, production, and sales of injectable preparations, focusing on cardiovascular, immune, and nervous system diseases, with revenue growth driven by the 'two-invoice system' and optimized customer structure, maintaining market leadership through balanced product portfolio, strong R&D, unique processes, and integrated supply chain - The company's main business is injectable preparations, with leading biochemical products covering cardiovascular, immune (anti-tumor), and nervous system therapeutic areas[32](index=32&type=chunk) - Performance growth was primarily driven by the implementation of the 'two-invoice system' policy, shifting the customer structure from small and medium distributors to large distribution partners, leading to significantly accelerated operating revenue growth[35](index=35&type=chunk) - The company holds a market leadership position with over **50%** market share in several product categories, including cardiovascular and immunomodulators[37](index=37&type=chunk) - Core competencies include - **Product Portfolio Stability**: Five leading products are developing in a balanced manner with high market shares, mitigating single-product dependency risk[39](index=39&type=chunk) - **R&D and Patents**: Possessing **42** national patent technologies, including **31** invention patents, with high proficiency in biomacromolecule purification technology[40](index=40&type=chunk)[41](index=41&type=chunk) - **Integrated Supply Chain**: Possessing a complete industrial chain from raw materials to multi-dosage form preparations, effectively diversifying risks[45](index=45&type=chunk) [Management Discussion and Analysis](index=15&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Overview](index=15&type=section&id=4.1%20%E6%A6%82%E8%BF%B0) In 2018, the company advanced its operational management, strategic layout, and R&D innovation, completing the acquisition of Junyuan Pharmaceutical, participating in a pharmaceutical industry investment fund, achieving phased results in key R&D projects like 'Angiogenesis Inhibitor Peptide for Injection' and 'Nafamostat Mesylate for Injection', implementing equity incentives for core personnel, and steadily progressing with fundraising projects - The company's five main products maintained market competitive advantages, with **Deoxyribonucleotide Sodium Injection** having the highest revenue share at **35.76%** and the highest gross margin at **91.34%**[50](index=50&type=chunk) - In R&D, 'Nafamostat Mesylate for Injection' entered Phase III clinical trials, and 'Angiogenesis Inhibitor Peptide for Injection' entered Phase I clinical trials[54](index=54&type=chunk) - Strategic initiatives included acquiring **100%** equity of Junyuan Pharmaceutical to extend the industrial chain, and investing **100 million Yuan** to establish Suzhou Danqing Phase II Innovative Pharmaceutical Industry Investment Partnership, leveraging a 'industry + capital' platform advantage[58](index=58&type=chunk)[59](index=59&type=chunk) - Construction of fundraising projects progressed steadily, but projects like the 'New Pharmaceutical Production Base' had their estimated completion time adjusted to **end of 2019** due to external factors[57](index=57&type=chunk) [Main Business Analysis](index=23&type=section&id=4.2%20%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's operating revenue grew by **90.37%**, primarily from pharmaceutical manufacturing, with immune system drugs seeing the fastest growth at **121.40%**, and Central and Southern China regions experiencing explosive revenue growth of **202.92%** and **407.15%** respectively, while overall gross margin increased from **76.95%** to **86.46%**, sales expenses surged by **274.82%** due to increased market promotion, and R&D investment rose by **96.38%** Operating Revenue Composition (by Product) | Product Category | 2018 Revenue (Yuan) | Revenue Share | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Immune System Drugs | 769,371,111.40 | 53.89% | 121.40% | | Nervous System Drugs | 207,689,792.42 | 14.55% | 65.39% | | Cardiovascular and Cerebrovascular Drugs | 439,946,037.30 | 30.81% | 63.75% | Gross Margin by Product | Product Category | Operating Revenue (Yuan) | Operating Cost (Yuan) | Gross Margin | Gross Margin Change from Previous Year | | :--- | :--- | :--- | :--- | :--- | | Immune System Drugs | 769,371,111.40 | 88,917,804.96 | 88.44% | 11.79% | | Nervous System Drugs | 207,689,792.42 | 39,685,832.48 | 80.89% | 10.26% | | Cardiovascular and Cerebrovascular Drugs | 439,946,037.30 | 63,250,090.60 | 85.62% | 5.34% | Period Expense Changes | Expense Item | 2018 (Yuan) | 2017 (Yuan) | Year-on-Year Change | Main Change Explanation | | :--- | :--- | :--- | :--- | :--- | | Sales Expenses | 828,431,196.33 | 221,019,934.30 | 274.82% | Increase in marketing conference fees, academic promotion fees, etc | | Administrative Expenses | 58,946,022.99 | 41,715,830.38 | 41.30% | Increase in equity incentive expenses and intangible asset amortization | | R&D Expenses | 31,927,796.80 | 16,258,343.92 | 96.38% | Increased R&D investment in pipeline products | - Net cash flow from operating activities was **147 million Yuan**, a **35.40%** year-on-year increase, primarily due to higher sales revenue, while net cash flow from investing activities was **-1.025 billion Yuan**, a significant **364.50%** year-on-year decrease, mainly due to reduced short-term bank wealth management investments[87](index=87&type=chunk)[88](index=88&type=chunk) [Assets and Liabilities Status](index=29&type=section&id=4.3%20%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5) As of year-end 2018, the company's total assets reached **2.761 billion Yuan**, a **12.52%** increase from the beginning of the year, with a significant shift in asset structure as monetary funds decreased from **60.11%** to **20.76%** of total assets due to investments in short-term wealth management products, while accounts receivable increased from **3.26%** to **8.84%**, and construction in progress rose from **10.23%** to **14.49%** Significant Changes in Asset Composition | Asset Item | Year-end 2018 Amount (Yuan) | Percentage of Total Assets | Year-end 2017 Amount (Yuan) | Percentage of Total Assets | Explanation of Change | | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 573,089,214.77 | 20.76% | 1,474,817,657.53 | 60.11% | Due to short-term bank wealth management investments not matured at period-end | | Accounts Receivable | 243,999,879.73 | 8.84% | 80,062,742.49 | 3.26% | Due to sales growth | | Construction in Progress | 399,957,617.82 | 14.49% | 250,964,292.65 | 10.23% | Continued investment in fundraising projects | [Investment Status Analysis](index=29&type=section&id=4.4%20%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) During the reporting period, the company's total external equity investment was **83.286 million Yuan**, a **278.57%** year-on-year increase, including the acquisition of **100%** equity in Shenyang Junyuan Pharmaceutical for **53.286 million Yuan** and a **30 million Yuan** investment in Suzhou Danqing Phase II Innovative Pharmaceutical Industry Investment Partnership, with **545 million Yuan** of raised funds cumulatively invested and **631 million Yuan** remaining unused for ongoing production base and industrialization projects 2018 Significant Equity Investments | Investee Company | Investment Method | Investment Amount (Yuan) | Shareholding Ratio | | :--- | :--- | :--- | :--- | | Shenyang Junyuan Pharmaceutical Co., Ltd | Acquisition | 53,286,000.00 | 100.00% | | Suzhou Danqing Phase II Innovative Pharmaceutical Industry Investment Partnership | New Establishment | 30,000,000.00 | 4.46% | - As of the end of the reporting period, the company had cumulatively invested **544.59 million Yuan** of raised funds, with an unused balance of **630.65 million Yuan**, primarily held in special accounts and used for time deposits and wealth management products[99](index=99&type=chunk) - The progress of some fundraising projects fell short of expectations, with the 'New Pharmaceutical Production Base Project' and 'New Cardiovascular and Immunomodulatory Product Industrialization Project' having their estimated completion dates extended to **December 31, 2019**, due to external factors[102](index=102&type=chunk) [Analysis of Major Holding and Participating Companies](index=33&type=section&id=4.5%20%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) During the reporting period, Shenyang Junyuan was added to the company's consolidated scope, while key subsidiary Sai'er Bio achieved **10.744 million Yuan** in operating revenue and **1.178 million Yuan** in net profit, and the newly acquired Shenyang Junyuan, still in integration, reported no operating revenue and a net loss of **0.557 million Yuan** Operating Performance of Major Subsidiaries | Company Name | Type | Operating Revenue (Yuan) | Net Profit (Yuan) | | :--- | :--- | :--- | :--- | | Sai'er Bio | Subsidiary | 10,744,002.68 | 1,177,645.69 | | Shenyang Junyuan | Subsidiary | 0.00 | -557,009.45 | [Outlook on Company's Future Development](index=34&type=section&id=4.6%20%E5%85%AC%E5%8F%B8%E6%9C%AA%E6%9D%A5%E5%8F%91%E5%B1%95%E7%9A%84%E5%B1%95%E6%9C%9B) Facing a slowing and stricter pharmaceutical industry, the company aims to become a 'big health enterprise group' by strategically developing high-end, oral, and traditional Chinese medicine preparations, enriching its product line, expanding scale, and enhancing core competitiveness through R&D, collaborations, and M&A, with 2019 plans focusing on fundraising project completion, refined marketing, R&D team building, and active acquisition pursuits - Industry Trend: The pharmaceutical industry is entering a new cycle of low growth, strict regulation, and high entry barriers, highlighting the value of products and R&D[109](index=109&type=chunk) - Company Development Strategy: Establish four major platforms—R&D innovation, pharmaceutical industrial chain, collaboration, and industrial finance—to advance towards a 'big health enterprise group' while pursuing external expansion[117](index=117&type=chunk) - 2019 Operating Plan - **Production**: Promote the completion of fundraising projects and advance GMP certification for subsidiaries[118](index=118&type=chunk) - **Marketing**: Strengthen regional management, optimize resource allocation, and intensify academic promotion efforts[119](index=119&type=chunk)[121](index=121&type=chunk) - **R&D**: Strengthen re-evaluation of core products, promote new product development, and enhance external collaborations[122](index=122&type=chunk) - **Talent**: Recruit personnel for the new production base and improve the talent management system[123](index=123&type=chunk) - **M&A**: Actively utilize M&A funds to seek acquisition opportunities with peer or upstream/downstream enterprises[123](index=123&type=chunk) [Significant Matters](index=40&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Profit Distribution and Equity Incentives](index=40&type=section&id=5.1%20%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E5%8F%8A%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1) In 2018, the company implemented its 2017 profit distribution plan and proposed the 2018 plan, with cash dividends exceeding **20%** of net profit for the past three years, and launched a 2018 restricted stock incentive plan, granting **4.166 million** restricted shares to **88** core employees to incentivize and retain key talent Cash Dividend Situation Over the Past Three Years | Dividend Year | Cash Dividend Amount (Yuan) | Ratio of Net Profit Attributable to Ordinary Shareholders of the Listed Company in Consolidated Financial Statements | | :--- | :--- | :--- | | 2018 | 58,099,920.00 | 20.52% | | 2017 | 57,600,000.00 | 20.45% | | 2016 | 60,000,000.00 | 23.22% | - The company implemented the 2018 Restricted Stock Incentive Plan, granting **4.166 million** restricted shares (out of **4.1982 million** initially planned) to **88** (out of **91** initially planned) incentive recipients on **August 21, 2018**[152](index=152&type=chunk)[153](index=153&type=chunk) [Significant Contracts and Transactions](index=53&type=section&id=5.2%20%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E4%BA%A4%E6%98%93) During the reporting period, the company had no significant entrustment, contracting, leasing, guarantee, or related party transactions, actively engaging in entrusted wealth management with idle raised and own funds totaling **1.115 billion Yuan**, primarily in bank wealth management products, while completing the acquisition of Shenyang Dongang Pharmaceutical Co., Ltd., renamed Shenyang Junyuan Pharmaceutical Co., Ltd., and its subsidiary Sai'er Bio established a Tianjin branch and obtained an expanded drug production license Overview of Entrusted Wealth Management During the Reporting Period | Specific Type | Fund Source | Amount Incurred (10,000 Yuan) | Unmatured Balance (10,000 Yuan) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Raised Funds | 51,500 | 51,500 | | Bank Wealth Management Products | Own Funds | 60,000 | 27,000 | | **Total** | | **111,500** | **78,500** | - Significant Subsidiary Matters - **Shenyang Junyuan**: Completed the bidding, acquisition, and business registration change for **100%** equity of Shenyang Dongang Pharmaceutical, renaming it 'Shenyang Junyuan Pharmaceutical Co., Ltd'[177](index=177&type=chunk)[178](index=178&type=chunk) - **Sai'er Bio**: Established a branch in Tianjin and obtained an expanded 'Drug Production License' from the Beijing Municipal Drug Administration[179](index=179&type=chunk) [Share Changes and Shareholder Information](index=60&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) [Share Change Status](index=60&type=section&id=6.1%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's total share capital increased from **240 million** to **484 million** shares, primarily due to the lifting of lock-up on pre-IPO shares, a 10-for-10 capital reserve to share transfer, and the issuance of **4.166 million** restricted shares under an equity incentive plan, reducing restricted shares from **64.80%** to **49.04%** of total shares Summary of Share Changes | Share Class | Quantity Before Change | Quantity After Change | Reason for Change | | :--- | :--- | :--- | :--- | | Restricted Shares | 155,520,000 | 237,446,000 | Equity incentive issuance, capital reserve conversion, executive lock-up | | Unrestricted Shares | 84,480,000 | 246,720,000 | Restricted share release, capital reserve conversion | | **Total Share Capital** | **240,000,000** | **484,166,000** | Capital reserve conversion and equity incentive issuance | - Main reasons for share changes include - In **June 2018**, **155.52 million** pre-IPO shares became tradable[182](index=182&type=chunk) - In **June 2018**, the capital reserve to share transfer plan of '10 shares for every 10 shares' was implemented, increasing total share capital to **480 million** shares[183](index=183&type=chunk) - In **September 2018**, the initial grant of the restricted stock incentive plan was completed, adding **4.166 million** shares[183](index=183&type=chunk) [Shareholder Information](index=63&type=section&id=6.2%20%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) As of year-end 2018, the company had **20,599** shareholders, with controlling shareholder and de facto controller Mr. Ma Biao holding **49.25%** of shares, and Mr. Ma Biao, Ms. Ma Li (**11.78%**), and Ms. Liu Shuqin (**3.21%**) acting in concert (mother-son, sibling relationship), collectively holding over **64%** of shares - As of the end of the reporting period, the company had **20,599** common shareholders[193](index=193&type=chunk) Top Three Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Ratio | Shares Held at Period-End | | :--- | :--- | :--- | :--- | | Ma Biao | Domestic Natural Person | 49.25% | 238,464,000 | | Ma Li | Domestic Natural Person | 11.78% | 57,024,000 | | Liu Shuqin | Domestic Natural Person | 3.21% | 15,552,000 | - The company's controlling shareholder and de facto controller is Mr. Ma Biao, who is a sibling to Ms. Ma Li, and Ms. Liu Shuqin is their mother[194](index=194&type=chunk)[196](index=196&type=chunk) [Preferred Shares Related Information](index=67&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E4%BC%98%E5%85%88%E8%82%A1%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) [Overview of Preferred Shares](index=67&type=section&id=7.1%20%E4%BC%98%E5%85%88%E8%82%A1%E6%A6%82%E5%86%B5) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[201](index=201&type=chunk) [Directors, Supervisors, Senior Management, and Employees](index=68&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%92%8C%E5%91%98%E5%B7%A5%E6%83%85%E5%86%B5) [Changes in Directors, Supervisors, Senior Management and Their Shareholdings](index=68&type=section&id=8.1%20%E8%91%A3%E7%9B%91%E9%AB%98%E5%8F%98%E5%8A%A8%E4%B8%8E%E6%8C%81%E8%82%A1) During the reporting period, some directors, supervisors, and senior management personnel changed due to term expiration, while their shareholdings increased due to capital reserve to share transfer and equity incentive plans, with Chairman Ma Biao's holdings reaching **238 million** shares at period-end, and executive compensation determined by the Remuneration and Assessment Committee based on performance - On **February 1, 2018**, several company directors, independent directors, supervisors, and the chief engineer resigned due to term expiration[206](index=206&type=chunk) - Some directors and senior executives increased their shareholdings through the 2018 Restricted Stock Incentive Plan, with Vice General Manager Wang Xuefeng and Marketing Director Zhang Fan each receiving **150,000** shares[222](index=222&type=chunk) [Employee Information](index=74&type=section&id=8.2%20%E5%91%98%E5%B7%A5%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had **512** employees, with production and technical personnel constituting the majority at **32.6%** and **30.1%** respectively, and approximately **67%** of employees holding college degrees or higher, while the company has established a market-aligned and performance-based compensation policy and implemented employee training programs including internal and external training Employee Professional Composition | Professional Category | Number of People | Percentage | | :--- | :--- | :--- | | Production Personnel | 167 | 32.6% | | Sales Personnel | 73 | 14.3% | | Technical Personnel | 154 | 30.1% | | Financial Personnel | 25 | 4.9% | | Administrative Personnel | 93 | 18.1% | | **Total** | **512** | **100.0%** | - The company's compensation policy ensures alignment with market levels, combining job analysis and performance appraisal to balance efficiency and fairness[225](index=225&type=chunk) [Corporate Governance](index=77&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86) [Overview of Corporate Governance](index=77&type=section&id=9.1%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E6%A6%82%E5%86%B5) The company operates strictly in accordance with laws and regulations like the 'Company Law' and 'Securities Law', with its corporate governance meeting regulatory requirements, maintaining independence from the controlling shareholder in business, personnel, assets, organization, and finance, holding **4** shareholder meetings, **8** board meetings, and **8** supervisory board meetings during the reporting period, and its specialized committees (Audit, Remuneration, Strategy, Nomination) actively fulfilled their duties by reviewing financial matters, executive compensation, major investments, and personnel nominations - The company's corporate governance structure is sound, with its actual status complying with normative documents on listed company governance issued by the China Securities Regulatory Commission[230](index=230&type=chunk)[238](index=238&type=chunk) - The company is independent of its controlling shareholder in business, personnel, assets, organization, and finance, possessing autonomous operational capabilities[239](index=239&type=chunk)[240](index=240&type=chunk) - The Board of Directors' four special committees (Audit, Remuneration and Assessment, Strategy, Nomination) held multiple meetings during the reporting period, fulfilling their respective duties by reviewing significant matters including annual financial reports, executive compensation, equity incentives, external investments, and director re-elections[245](index=245&type=chunk)[246](index=246&type=chunk)[248](index=248&type=chunk) - Based on the '2018 Internal Control Self-Assessment Report', the company believes its internal controls are effective, with no material weaknesses or significant deficiencies in financial or non-financial reporting[252](index=252&type=chunk)[253](index=253&type=chunk) [Corporate Bonds Related Information](index=84&type=section&id=%E7%AC%AC%E5%8D%81%E8%8A%82%20%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) [Overview of Corporate Bonds](index=84&type=section&id=10.1%20%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8%E6%A6%82%E5%86%B5) The company has no publicly issued and listed corporate bonds on stock exchanges that are either unmatured or have not been fully redeemed as of the approval date of the annual report - The company has no outstanding or unredeemed corporate bonds[256](index=256&type=chunk) [Financial Report](index=85&type=section&id=%E7%AC%AC%E5%8D%81%E4%B8%80%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) [Audit Report](index=85&type=section&id=11.1%20%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) Grant Thornton (Special General Partnership) issued a standard unqualified audit opinion on the company's 2018 financial statements, affirming that they fairly present the company's financial position and operating results in all material respects, with key audit matters being 'provision for impairment of accounts receivable' and 'goodwill impairment' due to significant management judgments involved - The audit opinion type is a standard unqualified opinion[258](index=258&type=chunk) - Key Audit Matter One: Provision for impairment of accounts receivable; as of year-end 2018, accounts receivable balance was **257 million Yuan**, with a bad debt provision of **13.086 million Yuan**, listed as a key audit matter due to its materiality and complex judgment involved in assessment[263](index=263&type=chunk) - Key Audit Matter Two: Goodwill impairment; as of year-end 2018, the book balance of goodwill was **21.8651 million Yuan**, listed as a key audit matter due to its materiality and the significant management judgment required for impairment testing[267](index=267&type=chunk) [Financial Statements](index=90&type=section&id=11.2%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) Financial statements show the company's total assets increased from **2.453 billion Yuan** to **2.761 billion Yuan**, operating revenue significantly grew to **1.428 billion Yuan**, but total profit slightly decreased from **331 million Yuan** to **330 million Yuan** due to sharp increases in sales and other costs, while operating cash flow remained positive at **147 million Yuan**, and share capital expanded from **240 million** to **484 million** shares through capital reserve conversion and restricted stock issuance Consolidated Balance Sheet Summary (Unit: Yuan) | Item | Period-End Balance | Period-Beginning Balance | | :--- | :--- | :--- | | Total Assets | 2,760,559,359.20 | 2,453,403,315.15 | | Total Liabilities | 205,073,804.97 | 133,912,073.01 | | Total Equity Attributable to Parent Company Owners | 2,554,113,066.35 | 2,318,173,172.59 | Consolidated Income Statement Summary (Unit: Yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Total Operating Revenue | 1,427,750,943.80 | 749,986,848.13 | | Total Operating Cost | 1,141,768,392.65 | 465,921,176.21 | | Total Profit | 330,618,035.25 | 331,386,637.47 | | Net Profit | 283,161,466.54 | 281,531,374.73 | Consolidated Cash Flow Statement Summary (Unit: Yuan) | Item | Current Period Amount | Prior Period Amount | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 146,516,272.45 | 108,212,673.95 | | Net Cash Flow from Investing Activities | -1,024,806,875.21 | 387,457,785.82 | | Net Cash Flow from Financing Activities | -23,437,840.00 | -60,000,000.00 | | Net Increase in Cash and Cash Equivalents | -901,728,442.76 | 435,670,459.77 | [Reference Documents Catalog](index=172&type=section&id=%E7%AC%AC%E5%8D%81%E4%BA%8C%E8%8A%82%20%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) [Reference Documents](index=172&type=section&id=12.1%20%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6) Reference documents for this report include the original annual report signed by the legal representative, original signed and sealed financial statements and audit report, and originals of all publicly disclosed documents and announcements during the reporting period - Reference documents include - Original Annual Report - Original Financial Statements - Original Audit Report - All publicly disclosed documents during the reporting period[665](index=665&type=chunk)[666](index=666&type=chunk)